Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Nutrition Reports
Published in: Current Nutrition Reports 4/2014

01-12-2014 | Public Health and Translational Medicine (PW Franks, Section Editor)

Prevention of Diabetes Through Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice

Authors: Mary A. Hoskin, George A. Bray, Kathy Hattaway, Prajakta A. Khare-Ranade, Jeremy Pomeroy, Linda N. Semler, Valarie A. Weinzierl, Judith Wylie-Rosett, for the Diabetes Prevention Program Research Group

Published in: Current Nutrition Reports | Issue 4/2014

Login to get access

Abstract

A number of strategies have been used to delay or prevent the development of type 2 diabetes mellitus (T2D) in high-risk adults, such as diet, exercise, medications, and surgery. This report focuses on the nutritional lessons learned from implementation of the Intensive Lifestyle Intervention (ILI) in the DPP and its follow-up DPPOS that looked at weight loss through modification of diet and exercise. The Diabetes Prevention Program (DPP) is a large clinical trial, sponsored by the National Institutes of Health, designed to look at several strategies to prevent conversion to type 2 diabetes (T2D) by adults with prediabetes (IGT/IFG), including ILI. The ~3800 ethnically diverse participants (46 % reported nonwhite race) were overweight, had impaired glucose tolerance (IGT), and impaired fasting glucose (IFG). Treatments were assigned randomly. The Diabetes Prevention Program Outcomes Study (DPPOS) is a follow-up study that evaluated the long-term outcomes of the clinical trial.
Trial registration: DPP is registered in www.​clinicaltrials.​gov (NCT00004992) and DPPOS (NCT 00038727).
Appendix
Available only for authorised users
Literature
1.
Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382–93.PubMedCentralPubMedCrossRef
2.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRef
3.
Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Haffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;14(374):1677–86.
4.
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22(4):623–34.CrossRef
5.
Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–71.CrossRef
6.••
The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–30. The DPP and its Outcomes study demonstrated that both ILI and metformin could prevent diabetes in those at high risk for at least 10 years post-randomization and this investment provides good value for funds invested in prevention. These data are important for building meaningful translation of diabetes prevention strategies.PubMedCentralCrossRef
7.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.
8.
Mayer-Davis EJ, Sparks KC, Hirst K, et al. Dietary intake in the Diabetes Prevention Program cohort: baseline and 1 year post randomization. Ann Epidemol. 2004;14(10):763–72.CrossRef
9.••
Jaacks LM, Ma Y, Davis N, Delahanty LM, Mayer-Davis EJ, Franks PW, et al. Long-term changes in dietary intake and food behaviors in the Diabetes Prevention Program Outcomes Study. Diabet Med. 2014. doi:10.​1111/​dme.​12500. This analysis was of long term changes in food intake and diet-related behaviors in the DPP. Significant differences remained between randomized groups up to 9 years.PubMed
10.••
Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, et al. Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet. 2013;113(11):1455–64. The DPP’s Intensive Lifestyle Intervention resulted in reductions of total energy intake for up to 9 years. Initial success at goal achievement predicted long-term success at maintaining changes achieved.PubMedCrossRef
11.
Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, et al. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc. 2006;38(5):826–32.PubMedCentralPubMedCrossRef
12.
13.
Hoskin M, Begay S, Bolin P, Hermes J, Ingraham L, Killean T, et al. Providing lifestyle interventions in American Indian communities. Obes Manag J. 2005;1(6):251–5.CrossRef
14.
Wylie-Rosett J, Delahanty L. An integral role of the dietitian: implications of the Diabetes Prevention Program. J Am Diet Assoc. 2002;102(8):1065–8.PubMedCentralPubMed
15.••
Venditti E, Wylie-Rosett J, Delahanty L, Mele L, Hoskin M, Edelstein S, et al. Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act. 2014;11(1):16. The coaching approaches that were critical to the success of the DPP Intensive Lifestyle Intervention are analyzed and reviewed here. This is a critical piece to the implementation of the highly effective intervention.PubMedCentralPubMedCrossRef
16.
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7.PubMedCentralPubMedCrossRef
17.•
Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, et al. Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med. 2013;28(12):1629–36. These researchers looked at what predicts reduced diabetes risk; weight and glucose at 6 and 12 months.PubMedCrossRef
18.
Ratner RE, Chitson PA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–9.PubMedCentralPubMedCrossRef
19.••
Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, et al. Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes. Diabetes Care. 2014;37(4):909–11. These data suggest that diabetes-associated GRS is associated with the development of GDM due to reduced beta cell function but did not predict progression to diabetes or modulate the response to the interventions.PubMedCrossRef
20.
Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28(4):888–94.PubMedCrossRef
21.
Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: for the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32(4):726–32.PubMedCentralPubMedCrossRef
22.••
Orchard TJ, Temprosa M, Barrett-Connor E, Fowler S, Goldberg R, Mather K, et al. Long term effects of the Diabetes Prevention Program’s interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30(1):46–55. CVD risk reduction is important to evaluate when looking at methods to prevent diabetes. In the DPP and DPPOS, the Intensive Lifestyle Intervention achieved, with fewer medications, a comparable CVD risk reduction as the other treatment groups.PubMedCentralPubMedCrossRef
23.
Goldberg RB, Temprosa M, Otvos J, Brunzell J, Marcovina SM, Mather KJ, et al. Lifestyle and metformin treatment favorably influence lipoprotein sub-fraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98(10):3989–98.PubMedCentralPubMedCrossRef
24.
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–9.PubMedCentralPubMedCrossRef
25.••
Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, et al. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab. 2013;16(4):326–33. The researchers associated MetS and its components with diabetes risk in DPP participants, all of whom had IGT at baseline. They then assessed the intervention-related changes in the components of MetS and their correlations with the development of T2D.PubMedCrossRef
26.
Bray GA, Fujimoto W, Jablonski K, Barrett-Connor E, Haffner S, Hubbard V, et al. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity (Silver Spring). 2006;14(11):2107–17.CrossRef
27.
Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes. 2007;56(6):1680–5.PubMedCentralPubMedCrossRef
28.
Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res. 2004;12(9):1426–34.PubMedCrossRef
29.
Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, et al. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcome. Int J Obes (Lond). 2008;32(10):1537–44.CrossRef
30.
Price DW, Ma Y, Rubin RR, Perreault L, Bray GA, Marrero D, et al. Depression as a predictor of weight regain among successful weight losers in the Diabetes Prevention Program. Diabetes Care. 2013;36(2):216–21.PubMedCentralPubMedCrossRef
31.
Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2010;33(12):2549–51.PubMedCentralPubMedCrossRef
32.
Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, et al. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care. 2005;28(4):830–7.PubMedCrossRef
33.
Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61(10):1075–81.PubMedCentralPubMedCrossRef
34.
35.
Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29(2):385–90.PubMedCentralPubMedCrossRef
36.
Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566–72.PubMedCrossRef
37.
Hivert M-F, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes. 2011;60:1340–8.PubMedCentralPubMedCrossRef
38.
Herman WH, Hoerger TJ, Brandle M, Diabetes Prevention Program Research Group, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.PubMedCentralPubMedCrossRef
39.••
Herman WH, Edelstein SL, Ratner RE, The Diabetes Prevention Program Research Group, et al. Effectiveness and cost – effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202. The analysis of cost-effectiveness of the DPP and DPPOS treatment groups for those participants who were adherent to the treatments revealed that the treatments were cost saving or cost effective compared with placebo. Costs for individual and group classes were analyzed. These treatments to prevent diabetes represent a good value for the cost.PubMedCentralPubMed
40.
Simmons RK, Unwin N, Griffin SJ. International Diabetes Federation: an update of the evidence concerning the prevention of type 2 diabetes. Diabetes Res Clin Pract. 2010;87(2):143–9.PubMedCrossRef
41.•
Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the diabetes prevention program? Health Aff. 2012;31:67–75. They evaluated the effectiveness of 28 US-based studies applying the DPP ILI for people at high risk of T2D. Change in weight was about 4% of initial body weight and these results were similar in programs that delivered the intervention utilizing clinically trained professionals or lay educators.CrossRef
42.•
Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis. Int J Behav Nutr Phys Act. 2014;11:2. These authors evaluated the efficacy and effectiveness of interventions that include diet, with both aerobic and resistance training, in behavioral weight loss programs designed to prevent diabetes.PubMedCentralPubMedCrossRef
43.•
Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014;37:922–33. A meta-analysis of 22 studies detailing the success of the translation the studies they reviewed. These programs were effective at achieving weight loss, with greater adherence to guidelines resulting in significantly greater weight loss.PubMedCrossRef
44.
Paulweber B, Valensi P, Lindström J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42 Suppl 1:S3–36.PubMedCrossRef
45.
National Institute for Health and Clinical Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: National Institute for Health and Clinical Excellence; 2012.
46.•
Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab. 2014. This review looked at interventions that used 15 different strategies to prevent T2D. Age of subject and amount of weight lost was related to the effectiveness of the interventions.
47.•
Sumamo Schellenberg E, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(8):543–51. Randomized clinical trials were identified that were of at least 3 months duration, included diet and exercise and at least one other component aimed at preventing T2D. Seven studies reported that lifestyle interventions decreased the risk for diabetes from the end of intervention up to 10 years after it. They concluded that comprehensive lifestyle interventions that include these components are effective in decreasing incidence of T2D in high risk patients and the benefit extends beyond the active intervention phase.CrossRef
48.
Yuen A, Sugeng Y, Weiland TJ, Jelani GA. Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Aust N Z J Public Health. 2010;34(2):172–8.PubMedCrossRef
49.
50.•
Ruggiero L, Castillo A, Quinn L, Hochwert M. Translation of the diabetes prevention program’s lifestyle intervention: role of community health workers. Curr Diab Rep. 2012;12(2):127–37. Many underserved communities affected by high rates of T2D have access to a health system that include Community Health Workers. This article provides an overview of studies involving these workers in prevention of T2D.PubMedCrossRef
51.
Kramer MK, Kriska AM, Venditti EM, Miller RG, Brooks MM, Burke LE, et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med. 2009;37(6):505–11.PubMedCrossRef
52.
Venditti E, Kramer M. Diabetes Prevention Program community outreach perspectives on lifestyle training and translation. Am J Prev Med. 2013;44:S339–45.PubMedCentralPubMedCrossRef
53.•
Luohua J, Spero MM, Janette B, William HG, Haixiao H, Kelly AJ, et al. Translating the Diabetes Prevention Program into American Indian and Alaska native communities. Diabetes Care. 2013;36(9):2027–34. Type 2 diabetes affects American Indians disproportionately, and in 2009 was twice the age-adjusted prevalence of non-Hispanic whites. Effective translation of the DPP into Native Communities with scarce resources and diverse health care settings and a highly mobile population will have an important positive impact.
54.
Vojta D, Koehler T, Longjohn M, Lever J, Caputo N. A coordinated national model for diabetes prevention: linking health systems to an evidence-based community program. Am J Prev Med. 2013;44:S301–6.PubMedCrossRef
Metadata
Title
Prevention of Diabetes Through Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice
Authors
Mary A. Hoskin
George A. Bray
Kathy Hattaway
Prajakta A. Khare-Ranade
Jeremy Pomeroy
Linda N. Semler
Valarie A. Weinzierl
Judith Wylie-Rosett
for the Diabetes Prevention Program Research Group
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Nutrition Reports / Issue 4/2014
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-014-0094-2

Other articles of this Issue 4/2014

Current Nutrition Reports 4/2014 Go to the issue

Public Health and Translational Medicine (PW Franks, Section Editor)

Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies

Public Health and Translational Medicine (PW Franks, Section Editor)

The EPIC-InterAct Study: A Study of the Interplay between Genetic and Lifestyle Behavioral Factors on the Risk of Type 2 Diabetes in European Populations

Public Health and Translational Medicine (PW Franks, Section Editor)

Diet, Lifestyle, and Genetic Risk Factors for Type 2 Diabetes: A Review from the Nurses’ Health Study, Nurses’ Health Study 2, and Health Professionals’ Follow-Up Study

Diabetes and Obesity (MR Carnethon, Section Editor)

Dietary Management of Diabetic Chronic Kidney Disease

Public Health and Translational Medicine (PW Franks, Section Editor)

The Role of Protein and Carbohydrates for Long-Term Weight Control: Lessons from the Diogenes Trial

Public Health and Translational Medicine (PW Franks, Section Editor)

The Look AHEAD Trial: A Review and Discussion of Its Outcomes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits